相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
James L. Gulley et al.
LANCET ONCOLOGY (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Sacha Gnjatic et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer
Marianne J. Ratcliffe et al.
CLINICAL CANCER RESEARCH (2017)
CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC
M. Socinski et al.
ANNALS OF ONCOLOGY (2016)
Programmed Death Ligand-1 Immunohistochemistry-A New Challenge for Pathologists A Perspective From Members of the Pulmonary Pathology Society
Lynette M. Sholl et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study
David Planchard et al.
CLINICAL LUNG CANCER (2016)
The Clinical Utility of PD-L1 Testing in Selecting Non-Small Cell Lung Cancer Patients for PD1/PD-L1-Directed Therapy
L. C. Villaruz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis
Omar Abdel-Rahman
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Naiyer A. Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Scott Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis
Pedro Aguiar et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer
Takehito Shukuya et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study
Scott Antonia et al.
LANCET ONCOLOGY (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Andreas H. Scheel et al.
MODERN PATHOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients
B. W. Higgs et al.
EUROPEAN JOURNAL OF CANCER (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
Abhisek Swaika et al.
MOLECULAR IMMUNOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Overall Survival and PD-L1 Expression in Metastasized Malignant Melanoma
Jules Gadiot et al.
CANCER (2011)
分享论文
